Top

Published in:

Open Access 01-09-2020 | Obesity | Review

Using genetics to decipher the link between type 2 diabetes and cancer: shared aetiology or downstream consequence?

Authors: Emma E. Vincent, Hanieh Yaghootkar

Published in: Diabetologia | Issue 9/2020

Abstract

Recent developments in the field of genetics have accelerated our understanding of the aetiology of complex diseases. Type 2 diabetes mellitus and cancer are no exception, with large-scale genome-wide association studies (GWAS) facilitating exploration of the underlying pathology. Here, we discuss how genetics studies can be used to investigate the relationship between these complex diseases. Observational epidemiological studies consistently report that people with type 2 diabetes have a higher risk of several types of cancer. Indeed, type 2 diabetes and cancer share many common risk factors, such as obesity, ageing, poor diet and low levels of physical activity. However, questions remain regarding the biological mechanisms that link these two diseases. Large-scale GWAS of type 2 diabetes and cancer allow us to consider the evidence for shared genetic architecture. Several shared susceptibility genes have been identified, yet tissue specificity and direction of effect must be taken into account when considering common genetic aetiology. We also consider how GWAS, and associated techniques such as Mendelian randomisation, allow us to dissect the link between the two diseases and address questions such as ‘Does type 2 diabetes cause cancer or is the increased risk observed driven by higher adiposity or another associated metabolic feature?’

Available only for authorised users

Diabetes UK (2019) Number of people with diabetes reaches 4.7 million. Available from www.diabetes.org.uk/about_us/news/new-stats-people-living-with-diabetes. Accessed 23 Jun 2020

Giovannucci E, Harlan DM, Archer MC et al (2010) Diabetes and cancer: a consensus report. Diabetes Care 33(7):1674–1685. https://doi.org/10.2337/dc10-0666 CrossRefPubMedPubMedCentral

Barroso I, McCarthy MI (2019) The genetic basis of metabolic disease. Cell 177(1):146–161. https://doi.org/10.1016/j.cell.2019.02.024 CrossRefPubMedPubMedCentral

Sud A, Kinnersley B, Houlston RS (2017) Genome-wide association studies of cancer: current insights and future perspectives. Nat Rev Cancer 17(11):692–704. https://doi.org/10.1038/nrc.2017.82 CrossRefPubMed

Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG (2012) Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55(6):1607–1618. https://doi.org/10.1007/s00125-012-2525-1 CrossRefPubMed

Adams JD, Vella A (2018) What can diabetes-associated genetic variation in TCF7L2 teach us about the pathogenesis of type 2 diabetes? Metab Syndr Relat Disord 16(8):383–389. https://doi.org/10.1089/met.2018.0024 CrossRefPubMedPubMedCentral

Folsom AR, Pankow JS, Peacock JM, Bielinski SJ, Heiss G, Boerwinkle E (2008) Variation in TCF7L2 and increased risk of colon cancer: The Atherosclerosis Risk in Communities (ARIC) study. Diabetes Care 31(5):905–909. https://doi.org/10.2337/dc07-2131 CrossRefPubMed

Schumacher FR, Schmit SL, Jiao S et al (2015) Genome-wide association study of colorectal cancer identifies six new susceptibility loci. Nat Commun 6(1):7138. https://doi.org/10.1038/ncomms8138 CrossRefPubMed

Zhang B, Jia W-H, Matsuda K et al (2014) Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk. Nat Genet 46(6):533–542. https://doi.org/10.1038/ng.2985 CrossRefPubMedPubMedCentral

10.

Burwinkel B, Shanmugam KS, Hemminki K et al (2006) Transcription factor 7-like 2 (TCF7L2) variant is associated with familial breast cancer risk: a case-control study. BMC Cancer 6(1):268. https://doi.org/10.1186/1471-2407-6-268 CrossRefPubMedPubMedCentral

11.

Michailidou K, Hall P, Gonzalez-Neira A et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45(4):353–361. https://doi.org/10.1038/ng.2563 CrossRefPubMedPubMedCentral

12.

Purrington KS, Slager S, Eccles D et al (2014) Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis 35(5):1012–1019. https://doi.org/10.1093/carcin/bgt404 CrossRefPubMed

13.

Ling Q, Dong F, Geng L et al (2013) Impacts of TCF7L2 gene polymorphisms on the susceptibility of hepatogenous diabetes and hepatocellular carcinoma in cirrhotic patients. Gene 522(2):214–218. https://doi.org/10.1016/j.gene.2013.03.089 CrossRefPubMed

14.

Agalliu I, Suuriniemi M, Prokunina-Olsson L et al (2008) Evaluation of a variant in the transcription factor 7-like 2 (TCF7L2) gene and prostate cancer risk in a population-based study. Prostate 68(7):740–747. https://doi.org/10.1002/pros.20732 CrossRefPubMedPubMedCentral

15.

Zhang M, Tang M, Fang Y et al (2018) Cumulative evidence for relationships between multiple variants in the VTI1A and TCF7L2 genes and cancer incidence. Int J Cancer 142(3):498–513. https://doi.org/10.1002/ijc.31074 CrossRefPubMed

16.

Shim H-J, Lee R, Shin M-H, Kim H-N, Kweon S-S (2016) Association between the TCF7L2 polymorphism and colorectal cancer does not differ by diabetes and obesity statuses. Cancer Epidemiol 45:108–111. https://doi.org/10.1016/j.canep.2016.10.012 CrossRefPubMed

17.

Sainz J, Rudolph A, Hoffmeister M et al (2012) Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. J Clin Endocrinol Metab 97(5):E845–E851. https://doi.org/10.1210/jc.2011-2565 CrossRefPubMed

18.

Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407):330–337. https://doi.org/10.1038/nature11252 CrossRef

19.

Pierce BL, Austin MA, Ahsan H (2011) Association study of type 2 diabetes genetic susceptibility variants and risk of pancreatic cancer: an analysis of PanScan-I data. Cancer Causes Control 22(6):877–883. https://doi.org/10.1007/s10552-011-9760-5 CrossRefPubMedPubMedCentral

20.

Zhao Z, Wen W, Michailidou K et al (2016) Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes Control 27(5):679–693. https://doi.org/10.1007/s10552-016-0741-6 CrossRefPubMedPubMedCentral

21.

Chen F, Wilkens LR, Monroe KR et al (2011) No association of risk variants for diabetes and obesity with breast cancer: the Multiethnic Cohort and PAGE studies. Cancer Epidemiol Biomark Prev 20(5):1039–1042. https://doi.org/10.1158/1055-9965.EPI-11-0135 CrossRef

22.

Hou N, Zheng Y, Gamazon ER et al (2012) Genetic susceptibility to type 2 diabetes and breast cancer risk in women of European and African ancestry. Cancer Epidemiol Biomark Prev 21(3):552–556. https://doi.org/10.1158/1055-9965.EPI-11-0979 CrossRef

23.

Paltoo D, Woodson K, Taylor P, Albanes D, Virtamo J, Tangrea J (2003) Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPAR-γ) gene and risk of prostate cancer among men in a large cancer prevention study. Cancer Lett 191(1):67–74. https://doi.org/10.1016/s0304-3835(02)00617-1 CrossRefPubMed

24.

Zmuda JM, Modugno F, Weissfeld JL et al (2006) Peroxisome proliferator-activated receptor-γ polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction. Oncology 70(3):185–189. https://doi.org/10.1159/000093805 CrossRefPubMed

25.

Kasper JS, Giovannucci E (2006) A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomark Prev 15(11):2056–2062. https://doi.org/10.1158/1055-9965.EPI-06-0410 CrossRef

26.

Machiela MJ, Lindström S, Allen NE et al (2012) Association of type 2 diabetes susceptibility variants with advanced prostate cancer risk in the Breast and Prostate Cancer Cohort Consortium. Am J Epidemiol 176(12):1121–1129. https://doi.org/10.1093/aje/kws191 CrossRefPubMedPubMedCentral

27.

Meyer TE, Boerwinkle E, Morrison AC et al (2010) Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomark Prev 19(2):558–565. https://doi.org/10.1158/1055-9965.EPI-09-0902 CrossRef

28.

Pierce BL, Ahsan H (2010) Genetic susceptibility to type 2 diabetes is associated with reduced prostate cancer risk. Hum Hered 69(3):193–201. https://doi.org/10.1159/000289594 CrossRefPubMedPubMedCentral

29.

Waters KM, Wilkens LR, Monroe KR et al (2011) No association of type 2 diabetes risk variants and prostate cancer risk: the multiethnic cohort and PAGE. Cancer Epidemiol Biomark Prev 20(9):1979–1981. https://doi.org/10.1158/1055-9965.EPI-11-0019 CrossRef

30.

Yu OHY, Foulkes WD, Dastani Z et al (2013) An assessment of the shared allelic architecture between type II diabetes and prostate cancer. Cancer Epidemiol Biomark Prev 22(8):1473–1475. https://doi.org/10.1158/1055-9965.EPI-13-0476 CrossRef

31.

Zeggini E, Scott LJ, Saxena R et al (2008) Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 40(5):638–645. https://doi.org/10.1038/ng.120 CrossRefPubMedPubMedCentral

32.

Thomas G, Jacobs KB, Yeager M et al (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40(3):310–315. https://doi.org/10.1038/ng.91 CrossRefPubMed

33.

Tang H, Dong X, Hassan M, Abbruzzese JL, Li D (2011) Body mass index and obesity- and diabetes-associated genotypes and risk for pancreatic cancer. Cancer Epidemiol Biomark Prev 20(5):779–792. https://doi.org/10.1158/1055-9965.EPI-10-0845 CrossRef

34.

Theodoropoulos G, Papaconstantinou I, Felekouras E et al (2006) Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12(31):5037–5043. https://doi.org/10.3748/wjg.v12.i31.5037 CrossRefPubMedPubMedCentral

35.

Krishnan A, Nair S, Pillai M (2007) Biology of PPARγ in cancer: a critical review on existing lacunae. Curr Mol Med 7(6):532–540. https://doi.org/10.2174/156652407781695765 CrossRefPubMed

36.

Shen H, Fridley BL, Song H et al (2013) Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun 4(1):1628. https://doi.org/10.1038/ncomms2629 CrossRefPubMed

37.

Pharoah PDP, Tsai Y-Y, Ramus SJ et al (2013) GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet 45(4):362–370. https://doi.org/10.1038/ng.2564 CrossRefPubMedPubMedCentral

38.

Small KS, Todorčević M, Civelek M et al (2018) Regulatory variants at KLF14 influence type 2 diabetes risk via a female-specific effect on adipocyte size and body composition. Nat Genet 50(4):572–580. https://doi.org/10.1038/s41588-018-0088-x CrossRefPubMedPubMedCentral

39.

Fan G, Sun L, Shan P et al (2015) Loss of KLF14 triggers centrosome amplification and tumorigenesis. Nat Commun 6(1):8450. https://doi.org/10.1038/ncomms9450 CrossRefPubMed

40.

Dupuis J, Langenberg C, Prokopenko I et al (2010) New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 42(2):105–116. https://doi.org/10.1038/ng.520 CrossRefPubMedPubMedCentral

41.

Morris AP, Voight BF, Teslovich TM et al (2012) Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 44(9):981–990. https://doi.org/10.1038/ng.2383 CrossRefPubMedPubMedCentral

42.

Dimas AS, Lagou V, Barker A et al (2014) Impact of type 2 diabetes susceptibility variants on quantitative glycemic traits reveals mechanistic heterogeneity. Diabetes 63(6):2158–2171. https://doi.org/10.2337/db13-0949 CrossRefPubMedPubMedCentral

43.

Grarup N, Rose CS, Andersson EA et al (2007) Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies. Diabetes 56(12):3105–3111. https://doi.org/10.2337/db07-0856 CrossRefPubMed

44.

Krishnamurthy J, Ramsey MR, Ligon KL et al (2006) p16INK4a induces an age-dependent decline in islet regenerative potential. Nature 443(7110):453–457. https://doi.org/10.1038/nature05092 CrossRefPubMed

45.

Pal A, Potjer TP, Thomsen SK et al (2016) Loss-of-function mutations in the cell-cycle control gene CDKN2A impact on glucose homeostasis in humans. Diabetes 65(2):527–533. https://doi.org/10.2337/db15-0602 CrossRefPubMed

46.

Pal A, Barber TM, Van de Bunt M et al (2012) PTEN mutations as a cause of constitutive insulin sensitivity and obesity. N Engl J Med 367(11):1002–1011. https://doi.org/10.1056/NEJMoa1113966 CrossRefPubMedPubMedCentral

47.

Mattis KK, Gloyn AL (2020) From genetic association to molecular mechanisms for islet-cell dysfunction in type 2 diabetes. J Mol Biol 432(5):1551–1578. https://doi.org/10.1016/j.jmb.2019.12.045 CrossRefPubMed

48.

Renehan AG, Yeh H-C, Johnson JA, Wild SH, Gale EAM, Møller H (2012) Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55(6):1619–1632. https://doi.org/10.1007/s00125-012-2526-0 CrossRefPubMed

49.

Davey Smith G, Hemani G (2014) Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet 23(R1):R89–R98. https://doi.org/10.1093/hmg/ddu328 CrossRefPubMedPubMedCentral

50.

Yarmolinsky J, Wade KH, Richmond RC et al (2018) Causal inference in cancer epidemiology: what is the role of Mendelian randomization? Cancer Epidemiol Biomark Prev 27(9):995–1010. https://doi.org/10.1158/1055-9965.EPI-17-1177 CrossRef

51.

Carreras-Torres R, Johansson M, Gaborieau V et al (2017) The role of obesity, type 2 diabetes, and metabolic factors in pancreatic cancer: a Mendelian randomization study. J Natl Cancer Inst 109(9). https://doi.org/10.1093/jnci/djx012

52.

Goto A, Yamaji T, Sawada N et al (2019) Diabetes and cancer risk: a Mendelian randomization study. Int J Cancer 146:712–719. https://doi.org/10.1002/ijc.32310 CrossRefPubMedPubMedCentral

53.

Nead KT, Sharp SJ, Thompson DJ et al (2015) Evidence of a causal association between insulinemia and endometrial cancer: a Mendelian randomization analysis. J Natl Cancer Inst 107(9). https://doi.org/10.1093/jnci/djv178

54.

Johansson M, Carreras-Torres R, Scelo G et al (2019) The influence of obesity-related factors in the etiology of renal cell carcinoma—a mendelian randomization study. PLoS Med 16(1):e1002724. https://doi.org/10.1371/journal.pmed.1002724 CrossRefPubMedPubMedCentral

55.

Yarmolinsky J, Relton CL, Lophatananon A et al (2019) Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: a Mendelian randomization analysis. PLoS Med 16(8):e1002893. https://doi.org/10.1371/journal.pmed.1002893 CrossRefPubMedPubMedCentral

56.

Rao Kondapally Seshasai S, Kaptoge S, Thompson A et al (2011) Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 364(9):829–841. https://doi.org/10.1056/NEJMoa1008862 CrossRefPubMedPubMedCentral

57.

Stocks T, Rapp K, Bjørge T et al (2009) Blood glucose and risk of incident and fatal cancer in the metabolic syndrome and cancer project (me-can): analysis of six prospective cohorts. PLoS Med 6(12):e1000201. https://doi.org/10.1371/journal.pmed.1000201 CrossRefPubMedPubMedCentral

58.

Park SM, Lim MK, Shin SA, Yun YH (2006) Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation Study. J Clin Oncol 24(31):5017–5024. https://doi.org/10.1200/JCO.2006.07.0243 CrossRefPubMed

59.

Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM (2005) Fasting serum glucose level and cancer risk in Korean men and women. JAMA 293(2):194–202. https://doi.org/10.1001/jama.293.2.194 CrossRefPubMed

60.

Pisani P (2008) Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 114(1):63–70. https://doi.org/10.1080/13813450801954451 CrossRefPubMed

61.

Pollak M (2009) Do cancer cells care if their host is hungry? Cell Metab 9(5):401–403. https://doi.org/10.1016/J.CMET.2009.04.006 CrossRefPubMed

62.

Johnson JA, Bowker SL (2011) Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials. Diabetologia 54(1):25–31. https://doi.org/10.1007/s00125-010-1933-3 CrossRefPubMed

63.

Carreras-Torres R, Johansson M, Haycock PC et al (2017) Obesity, metabolic factors and risk of different histological types of lung cancer: a Mendelian randomization study. PLoS One 12(6):e0177875. https://doi.org/10.1371/journal.pone.0177875 CrossRefPubMedPubMedCentral

64.

Shu X, Wu L, Khankari NK et al (2019) Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. Int J Epidemiol 48(3):795–806. https://doi.org/10.1093/ije/dyy201 CrossRefPubMed

65.

Jenab M, Riboli E, Cleveland RJ et al (2007) Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121(2):368–376. https://doi.org/10.1002/ijc.22697 CrossRefPubMed

66.

Lukanova A, Zeleniuch-Jacquotte A, Lundin E et al (2004) Prediagnostic levels of C-peptide, IGF-I, IGFBP -1, -2 and -3 and risk of endometrial cancer. Int J Cancer 108(2):262–268. https://doi.org/10.1002/ijc.11544 CrossRefPubMed

67.

Gunter MJ, Hoover DR, Yu H et al (2008) A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomark Prev 17(4):921–929. https://doi.org/10.1158/1055-9965.EPI-07-2686 CrossRef

68.

Di Sebastiano KM, Pinthus JH, Duivenvoorden WCM, Mourtzakis M (2018) Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. Obes Rev 19(7):1008–1016. https://doi.org/10.1111/obr.12674 CrossRefPubMed

69.

Ahern TP, Hankinson SE, Willett WC, Pollak MN, Eliassen AH, Tamimi RM (2013) Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer. Cancer Epidemiol Biomark Prev 22(10):1786–1796. https://doi.org/10.1158/1055-9965.EPI-13-0375 CrossRef

70.

Verheus M, Peeters PHM, Rinaldi S et al (2006) Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119(3):659–667. https://doi.org/10.1002/ijc.21861 CrossRefPubMed

71.

Irwin ML, Duggan C, Wang C-Y et al (2011) Fasting C-peptide levels and death resulting from all causes and breast cancer: the health, eating, activity, and lifestyle study. J Clin Oncol 29(1):47–53. https://doi.org/10.1200/JCO.2010.28.4752 CrossRefPubMed

72.

Ordener C, Cypriani B, Vuillermoz C, Adessi GL (1993) Epidermal growth factor and insulin induce the proliferation of guinea pig endometrial stromal cells in serum-free culture, whereas estradiol and progesterone do not. Biol Reprod 49(5):1032–1044. https://doi.org/10.1095/biolreprod49.5.1032 CrossRefPubMed

73.

Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M (2004) Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363(9418):1346–1353. https://doi.org/10.1016/S0140-6736(04)16044-3 CrossRefPubMed

74.

Murphy N, Knuppel A, Papadimitriou N et al (2020) Insulin-like growth factor-1, insulin-like growth factor-binding protein-3, and breast cancer risk: observational and Mendelian randomization analyses with ∼430 000 women. Ann Oncol 31(5):641–649. https://doi.org/10.1016/j.annonc.2020.01.066 CrossRefPubMed

75.

Bonilla C, Lewis SJ, Rowlands M-A et al (2016) Assessing the role of insulin-like growth factors and binding proteins in prostate cancer using Mendelian randomization: genetic variants as instruments for circulating levels. Int J Cancer 139(7):1520–1533. https://doi.org/10.1002/ijc.30206 CrossRefPubMedPubMedCentral

76.

Tan VY, Biernacka KM, Dudding T et al (2018) Reassessing the association between circulating vitamin d and igfbp-3: observational and Mendelian randomization estimates from independent sources. Cancer Epidemiol Biomark Prev 27(12):1462–1471. https://doi.org/10.1158/1055-9965.EPI-18-0113 CrossRef

77.

Nestler JE, Powers LP, Matt DW et al (1991) A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72(1):83–89. https://doi.org/10.1210/jcem-72-1-83 CrossRefPubMed

78.

Day FR, Thompson DJ, Helgason H et al (2017) Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. Nat Genet 49(6):834–841. https://doi.org/10.1038/ng.3841 CrossRefPubMedPubMedCentral

79.

Thompson DJ, O’Mara TA, Glubb DM et al (2016) CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer. Endocr Relat Cancer 23(2):77–91. https://doi.org/10.1530/ERC-15-0386 CrossRefPubMedPubMedCentral

80.

Dimou NL, Papadimitriou N, Gill D et al (2019) Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int J Epidemiol 48(3):807–816. https://doi.org/10.1093/ije/dyz107 CrossRefPubMedPubMedCentral

81.

Lauby-Secretan B, Scoccianti C, Loomis D et al (2016) Body fatness and cancer--viewpoint of the IARC Working Group. N Engl J Med 375(8):794–798. https://doi.org/10.1056/NEJMsr1606602 CrossRefPubMedPubMedCentral

82.

Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE (2006) Adult weight change and risk of postmenopausal breast cancer. JAMA 296(2):193–201. https://doi.org/10.1001/jama.296.2.193 CrossRefPubMed

83.

Tee MC, Cao Y, Warnock GL, Hu FB, Chavarro JE (2013) Effect of bariatric surgery on oncologic outcomes: a systematic review and meta-analysis. Surg Endosc 27(12):4449–4456. https://doi.org/10.1007/s00464-013-3127-9 CrossRefPubMedPubMedCentral

84.

Mariosa D, Carreras-Torres R, Martin RM, Johansson M, Brennan P (2019) Commentary: what can Mendelian randomization tell us about causes of cancer? Int J Epidemiol 48(3):816–821. https://doi.org/10.1093/ije/dyz151 CrossRefPubMedPubMedCentral

85.

Painter JN, O’Mara TA, Marquart L et al (2016) Genetic risk score Mendelian randomization shows that obesity measured as body mass index, but not waist:hip ratio, is causal for endometrial cancer. Cancer Epidemiol Biomark Prev 25(11):1503–1510. https://doi.org/10.1158/1055-9965.EPI-16-0147 CrossRef

86.

Dixon SC, Nagle CM, Thrift AP et al (2016) Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol 45(3):884–895. https://doi.org/10.1093/ije/dyw158 CrossRefPubMedPubMedCentral

87.

Gao C, Patel CJ, Michailidou K et al (2016) Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. Int J Epidemiol 45(3):896–908. https://doi.org/10.1093/ije/dyw129 CrossRefPubMedPubMedCentral

88.

Thrift AP, Shaheen NJ, Gammon MD et al (2014) Obesity and risk of esophageal adenocarcinoma and Barrett’s esophagus: a Mendelian randomization study. J Natl Cancer Inst 106(11):dju252. https://doi.org/10.1093/jnci/dju252 CrossRefPubMedPubMedCentral

89.

Langdon RJ, Richmond RC, Hemani G et al (2019) A phenome-wide Mendelian randomization study of pancreatic cancer using summary genetic data. Cancer Epidemiol Biomarkers Prev cebp.0036.2019. https://doi.org/10.1158/1055-9965.EPI-19-0036

90.

Lu Y, Gentiluomo M, Lorenzo-Bermejo J et al (2020) Mendelian randomisation study of the effects of known and putative risk factors on pancreatic cancer. J Med Genet. https://doi.org/10.1136/jmedgenet-2019-106200

91.

Thrift AP, Gong J, Peters U et al (2015) Mendelian randomization study of body mass index and colorectal cancer risk. Cancer Epidemiol Biomark Prev 24(7):1024–1031. https://doi.org/10.1158/1055-9965.EPI-14-1309 CrossRef

92.

Guo Q, Burgess S, Turman C et al (2017) Body mass index and breast cancer survival: a Mendelian randomization analysis. Int J Epidemiol 46(6):1814–1822. https://doi.org/10.1093/ije/dyx131 CrossRefPubMedPubMedCentral

93.

Guo Y, Warren Andersen S, Shu X-O et al (2016) Genetically predicted body mass index and breast cancer risk: Mendelian randomization analyses of data from 145,000 women of European descent. PLoS Med 13(8):e1002105. https://doi.org/10.1371/journal.pmed.1002105 CrossRefPubMedPubMedCentral

94.

Ooi BNS, Loh H, Ho PJ et al (2019) The genetic interplay between body mass index, breast size and breast cancer risk: a Mendelian randomization analysis. Int J Epidemiol 48(3):781–794. https://doi.org/10.1093/ije/dyz124 CrossRefPubMedPubMedCentral

95.

Richardson TG, Sanderson E, Elsworth B, Tilling K, Davey Smith G (2020) Use of genetic variation to separate the effects of early and later life adiposity on disease risk: Mendelian randomisation study. BMJ 369:m1203. https://doi.org/10.1136/bmj.m1203 CrossRefPubMedPubMedCentral

96.

Yaghootkar H, Scott RA, White CC et al (2014) Genetic evidence for a normal-weight “metabolically” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63(12):4369–4377. https://doi.org/10.2337/db14-0318 CrossRefPubMedPubMedCentral

97.

Yaghootkar H, Lotta LA, Tyrrell J et al (2016) Genetic evidence for a link between favorable adiposity and lower risk of type 2 diabetes, hypertension, and heart disease. Diabetes 65(8):2448–2460. https://doi.org/10.2337/db15-1671 CrossRefPubMed

98.

Ji Y, Yiorkas AM, Frau F et al (2019) Genome-wide and abdominal MRI data provide evidence that a genetically determined favorable adiposity phenotype is characterized by lower ectopic liver fat and lower risk of type 2 diabetes, heart disease, and hypertension. Diabetes 68(1):207–219. https://doi.org/10.2337/db18-0708 CrossRefPubMed

99.

Munafò MR, Davey Smith G (2018) Robust research needs many lines of evidence. Nature 553(7689):399–401. https://doi.org/10.1038/d41586-018-01023-3 CrossRefPubMed

100.

Mahajan A, Wessel J, Willems SM et al (2018) Refining the accuracy of validated target identification through coding variant fine-mapping in type 2 diabetes. Nat Genet 50(4):559–571. https://doi.org/10.1038/s41588-018-0084-1 CrossRefPubMedPubMedCentral

101.

Udler MS, Kim J, von Grotthuss M et al (2018) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: a soft clustering analysis. PLoS Med 15(9):e1002654. https://doi.org/10.1371/journal.pmed.1002654 CrossRefPubMedPubMedCentral

102.

Udler MS, McCarthy MI, Florez JC, Mahajan A (2019) Genetic risk scores for diabetes diagnosis and precision medicine. Endocr Rev 40(6):1500–1520. https://doi.org/10.1210/er.2019-00088 CrossRefPubMedPubMedCentral

103.

Izquierdo AG, Crujeiras AB (2019) Role of epigenomic mechanisms in the onset and management of insulin resistance. Rev Endocr Metab Disord 20(1):89–102. https://doi.org/10.1007/s11154-019-09485-0 CrossRefPubMed

104.

Parada H, Cleveland RJ, North KE et al (2019) Genetic polymorphisms of diabetes-related genes, their interaction with diabetes status, and breast cancer incidence and mortality: the Long Island Breast Cancer Study Project. Mol Carcinog 58(3):436–446. https://doi.org/10.1002/mc.22940 CrossRefPubMed

105.

Timpson NJ, Wade KH, Smith GD (2012) Mendelian randomization: application to cardiovascular disease. Curr Hypertens Rep 14(1):29–37. https://doi.org/10.1007/s11906-011-0242-7 CrossRefPubMed

106.

Au Yeung SL, Schooling CM (2019) Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study. BMJ Open Diabetes Res Care 7(1):e000872. https://doi.org/10.1136/bmjdrc-2019-000872 CrossRefPubMedPubMedCentral

107.

Au Yeung SL, Luo S, Schooling CM (2019) The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study. Diabetologia 62(9):1638–1646. https://doi.org/10.1007/s00125-019-4913-2 CrossRefPubMed

108.

Yarmolinsky J, Bull C, Walker V, Nounu A, Davey Smith G (2020) Mendelian randomization applied to pharmaceutical use: the case of metformin and lung cancer. Int J Epidemiol. https://doi.org/10.1093/ije/dyaa059

Title: Using genetics to decipher the link between type 2 diabetes and cancer: shared aetiology or downstream consequence?
Authors: Emma E. Vincent
Hanieh Yaghootkar
Publication date: 01-09-2020
Publisher: Springer Berlin Heidelberg
Keywords: Obesity
Obesity
Type 2 Diabetes
Published in: Diabetologia / Issue 9/2020
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-020-05228-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2020

Elevated pigment epithelium-derived factor induces diabetic erectile dysfunction via interruption of the Akt/Hsp90β/eNOS complex

Diabetes mellitus impairs circulating proangiogenic granulocytes

Preclinical and clinical studies of photobiomodulation therapy for macular oedema

Up front

Education and incident type 2 diabetes: quantifying the impact of differential exposure and susceptibility to being overweight or obese

Diabetic neuropathy: are we still barking up the wrong tree and is change finally in sight?

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials